Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats

Aim. To investigate the influence of probiotic pre-treatment on the permeation of the antidiabetic drug gliclazide in healthy and diabetic rats. Methods. Wistar rats (age 2-3 months, weight 350 ± 50 g) were randomly allocated into one of 4 groups (N = 16 each group): healthy control, healthy probiot...

Full description

Bibliographic Details
Main Authors: Al-Salami, Hani, Butt, G., Tucker, I., Skrbic, R., Golocorbin-Kon, S., Mikov, M.
Format: Journal Article
Published: 2008
Online Access:http://hdl.handle.net/20.500.11937/33230
_version_ 1848753887357435904
author Al-Salami, Hani
Butt, G.
Tucker, I.
Skrbic, R.
Golocorbin-Kon, S.
Mikov, M.
author_facet Al-Salami, Hani
Butt, G.
Tucker, I.
Skrbic, R.
Golocorbin-Kon, S.
Mikov, M.
author_sort Al-Salami, Hani
building Curtin Institutional Repository
collection Online Access
description Aim. To investigate the influence of probiotic pre-treatment on the permeation of the antidiabetic drug gliclazide in healthy and diabetic rats. Methods. Wistar rats (age 2-3 months, weight 350 ± 50 g) were randomly allocated into one of 4 groups (N = 16 each group): healthy control, healthy probiotic, diabetic control, and diabetic probiotic. Probiotics (75 mg/kg, equal quantities of Lactobacillus acidophilus, Bifidobacterium lactis, and Lactobacillus rhamnosus) were administered twice a day for three days to the appropriate groups after diabetes had been induced with alloxan i.v. 30 mg/kg. Rats were sacrificed, ileal tissues mounted in Ussing chambers and gliclazide (200 µg/mL) was administered for the measurement of the mucosal to serosal absorption Jss(MtoS) and serosal to mucosal secretion Jss(StoM) of gliclazide. Results. Treatment of healthy rats with probiotics reduced Jss(MtoS) of gliclazide from 1.2 ± 0.3 to 0.3 ± 0.1 µg/min/cm2 (P < 0.01) and increased Jss(StoM) from 0.6 ± 0.1 to 1.4 ± 0.3 (P < 0.01) resulting in net secretion while, in diabetic tissues, treatment with probiotics increased both Jss(MtoS) and Jss(StoM) fluxes of gliclazide to the comparable levels of healthy tissues resulting in net absorption. Discussion. In healthy rats, the reduction in Jss (MtoS) after probiotics administration could be explained by the production of bacterial metabolites that upregulate the mucosal efflux drug transporters Mrp2 that control gliclazide transport. In diabetic rats, the restored fluxes of gliclazide after probiotic treatment, suggests the normalization of the functionality of the drug transporters resulting in a net absorption. Conclusion. Probiotics may alter gliclazide transport across rat ileal tissue studied ex vivo. © 2008, Archives of Drug Information.
first_indexed 2025-11-14T08:31:39Z
format Journal Article
id curtin-20.500.11937-33230
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:31:39Z
publishDate 2008
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-332302023-02-22T06:24:16Z Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats Al-Salami, Hani Butt, G. Tucker, I. Skrbic, R. Golocorbin-Kon, S. Mikov, M. Aim. To investigate the influence of probiotic pre-treatment on the permeation of the antidiabetic drug gliclazide in healthy and diabetic rats. Methods. Wistar rats (age 2-3 months, weight 350 ± 50 g) were randomly allocated into one of 4 groups (N = 16 each group): healthy control, healthy probiotic, diabetic control, and diabetic probiotic. Probiotics (75 mg/kg, equal quantities of Lactobacillus acidophilus, Bifidobacterium lactis, and Lactobacillus rhamnosus) were administered twice a day for three days to the appropriate groups after diabetes had been induced with alloxan i.v. 30 mg/kg. Rats were sacrificed, ileal tissues mounted in Ussing chambers and gliclazide (200 µg/mL) was administered for the measurement of the mucosal to serosal absorption Jss(MtoS) and serosal to mucosal secretion Jss(StoM) of gliclazide. Results. Treatment of healthy rats with probiotics reduced Jss(MtoS) of gliclazide from 1.2 ± 0.3 to 0.3 ± 0.1 µg/min/cm2 (P < 0.01) and increased Jss(StoM) from 0.6 ± 0.1 to 1.4 ± 0.3 (P < 0.01) resulting in net secretion while, in diabetic tissues, treatment with probiotics increased both Jss(MtoS) and Jss(StoM) fluxes of gliclazide to the comparable levels of healthy tissues resulting in net absorption. Discussion. In healthy rats, the reduction in Jss (MtoS) after probiotics administration could be explained by the production of bacterial metabolites that upregulate the mucosal efflux drug transporters Mrp2 that control gliclazide transport. In diabetic rats, the restored fluxes of gliclazide after probiotic treatment, suggests the normalization of the functionality of the drug transporters resulting in a net absorption. Conclusion. Probiotics may alter gliclazide transport across rat ileal tissue studied ex vivo. © 2008, Archives of Drug Information. 2008 Journal Article http://hdl.handle.net/20.500.11937/33230 10.1111/j.1753-5174.2008.00006.x unknown
spellingShingle Al-Salami, Hani
Butt, G.
Tucker, I.
Skrbic, R.
Golocorbin-Kon, S.
Mikov, M.
Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats
title Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats
title_full Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats
title_fullStr Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats
title_full_unstemmed Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats
title_short Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats
title_sort probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats
url http://hdl.handle.net/20.500.11937/33230